number of published studies on "cost effectiveness" have increased by more than 30%. There is a large variability in CERs for same drugs for different indications, in some cases also varying by biomarkers. Primary care drugs had lower and less variable CERs than specialty drugs. Variations also exist in methodology used by different groups in modeling cost effectiveness, especially for time horizon and comparator. Majority of primary care drugs were modeled for a time horizon of 35-40 years or lifetime to demonstrate cost effectiveness. CONCLUSIONS: This analysis shows the range, variability and methods used for calculation of ICER values for these high budget impact drugs and provides lessons for executives and policy makers. 
PRS20 A COST-UTILITY ANALYSIS ON THE USE OF INDACATEROL FOR THE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE IN MEXICO

OBJECTIVES:
Chronic Obstructive Pulmonary Disease (COPD) has a huge impact on the quality of life (QOL) of patients, diminishing significantly their ability to work and their social activity. The objective of this study was to examine if the recently available treatment for COPD, indacaterol, improved the QOL more cost-effectively than the therapeutic alternatives already available. METHODS: A cost-utility analysis was performed from an institutional perspective (Mexican Institute of Social Security, IMSS). The comparators used were salmeterol and tiotropium, both alternatives available within the National Formulary and recommended by the National Treatment Guidelines for COPD; dosage regimens compared were indacaterol 300 g vs. tiotropium 18 g, and indacaterol 150 g vs. salmeterol 50 g. QOL data was taken from published literature; the parameter used was health-related (HR) QOL score using St. George's Respiratory Questionnaire (SGRQ). Resource use data was obtained from the institution; total direct costs of physician consults, lab and image tests, hospitalization and emergency room visits, and treatments were considered. The source of the unit costs was the institution, current for 2010. All costs are expressed in local currency (Mexican Pesos, MXP). The time horizon was less than 1 year; no discount rate was used. The analytical tool used to build the model was a decision tree. A probabilistic sensitivity analysis was performed through a Monte Carlo simulation with 100,000 iterations to confirm the robustness of the model.
RESULTS:
The results show a cost-utility ratio of $302 MXP for indacaterol, compared to $317 MXP for tiotropium. Likewise, a cost-utility ratio of $298 MXP for indacaterol was obtained, compared to $321 MXP for salmeterol, corroborating that indacaterol is a more cost-effective alternative (dominant) for the treatment of COPD. CONCLUSIONS: From an institutional perspective in Mexico, indacaterol improves QOL more cost-effectively (dominant) than either tiotropium or salmeterol for the treatment of COPD. Nasciben V Boehringer Ingelheim Brazil, Sao Paulo, Brazil OBJECTIVES: Chronic obstructive pulmonary disease (COPD) is a degenerative condition with symptoms, disability and impaired quality of life that according to PLATINO study has 15% of prevalence in the population over 40 years-old in Brazil with airflow obstruction who previously diagnosed with chronic bronchitis or emphysema. This study was designed to raise the resource use and economic impact of the exacerbation from COPD under the private healthcare system and the importance of maintenance treatment avoiding exacerbation. METHODS: A modified Delphi panel was conducted with specialist in COPD management to capture the clinical practice and use of resources to non severe and severe exacerbation treatment. Exacerbation reduction from maintenance treatment with tiotropium was taken from literature. Only direct medical costs were taken. For physician fees, procedure reimbursement, inpatient costs and drug costs were gathered from public lists (CBHPM 5 th , Kairos, PHROASA) that are the base for negotiations between providers and payers. The Brazilian guideline for economic evaluation was followed to guarantee the methodological robustness (Vianna, 2008) . Discounts were not applied for the time horizon of 1 year. RESULTS: For each non severe exacerbations the total cost was R$ 413 (physician fees for emergency, ambulatory care and consults in the hospital was R$ 180, R$ 210 for drugs and R$ 23 for oxygen therapy) and for severe cases total cost was R$ 5,221 per patient (average LOS of 11 and cost of R$ 2,228, physician fees for consults R$ 581, R$ 483 for exams and R$ 2583 for drugs and R$ 228 for oxygen therapy). Considering the incorporation of tiotropium in the maintenance phase, a reduction of up to 25% in the average exacerbation costs compared with the usual care of R$ 1,831. CONCLUSIONS: Tiotropium showed potential to reduce the economical burden of COPD due to exacerbation's reduction and delay. OBJECTIVES: Isoniazid is highly effective and widely used for TB prevention and treatment; however it must be used consistently for 6 to 9 months to treat latent TB, which is usually asymptomatic. The combination of long-term therapy and lack of symptoms results in high risk for non-adherence. The cost of subsequent treatment for patients with isoniazid resistance is estimated at $1 million per reactivation case prevented. These data highlight the need for more information about adherence with isoniazid in patients with latent TB. The specific aim of this study was to document adherence patterns in patients with latent TB and examine associations with patient characteristics. We also examined patient's attitudes toward intentional nonadherence in relation to medical doubts, lack of social support, and medication side effects by using the Temptation to Skip Therapy (TEST) scale. METHODS: Questionnaires were completed at baseline by 211 isoniazid treated patients (aged 18-66) at the Rhode Island Tuberculosis Clinic. Adherence was subsequently measured at 6 and 9 months. The average score was computed for each TEST subscale and the association with each subscale and the Morisky Medication Adherence Scale (MAS) was examined. RESULTS: Adherence to INH therapy was 45% (by MAS). Latent TB patients scored highest on the Side Effect (Meanϭ1.62) and lowest on the TEST Medical Doubt subscale (Mean ϭ 1.47). Non-Whites exhibited higher mean scores on the Medical Doubt subscale indicating uncertainty toward the need for therapy. Patients with higher scores on the Medical Doubt and Side Effect subscales had higher non-adherence levels. CONCLUSIONS: Latent TB patients exhibited low adherence with isoniazid therapy. Fear of side effects and doubts about the need for medication were related to discontinuation of therapy. Better understanding of attitudes toward isoniazid therapy may be beneficial for improving adherence, and reducing costs associated with isoniazid treatment.
PRS21 RESOURCE USE AND COSTS OF EXACERBATION MANAGEMENT OF CHRONIC OBSTRUTIVE PULMONARY DISEASE PATIENTS UNDER THE PRIVATE HEALTHCARE SYSTEM IN BRAZIL: ROLE OF MAINTENANCE TREATMENT IN THE EXACERBATION PREVENTION IN SEVERE PATIENTS
PRS24 IMPACT OF MORBIDITY, PSYCHOLOGICAL DISTRESS AND LUNG FUNCTION ON PHYSICAL FUNCTIONING IN A RETIRED POPULATION
Roberts M, Mapel D LCF Research, Albuquerque, NM, USA OBJECTIVES: Physical functioning scales have been used to assess risk for disability, propensity for healthcare utilization, and impact on quality of life (QOL) scores. Understanding related factors in a nationally representative older population is important for designing effective physical functioning improvement programs, potentially decreasing utilization and increasing QOL. METHODS: To measure impact of demographics, morbidities, psychological distress and lung function on physical functioning among the retired, a retrospective main effects analysis of data from the Health and Retirement Study (HRS) for subjects surveyed in 2006 and 2008 was performed on a sample of 13,129 patients aged Ͼ50 years (M ϭ 66.14; 45.9% male) with lung function measurement (peak expiratory flow (PEF)), and psychological distress (symptoms of anxiety and depression) assessment (8 question Center for Epidemiologic Studies Depression Scale (CES-D8)), and self-reported confirmation of morbidity diagnoses. Morbidities were diabetes (19.4%), chronic obstructive pulmonary disease (COPD) (9.8%), heart disease (23.6%), cancer (13.7%), and stroke (6.0%). RESULTS: In a weighted multiple regression model of physical function difficulty score, 49% of the variance was explained by analyzed variables. In a weighted logistic regression model for difficulties with Ͼ4 physical functions (maxϭ12), adjusted for age and race, odds were significantly higher for subjects reporting morbidities of frequent pain (odds ratio range (ORR) 6.0-7.7), COPD (ORR 2.4-3.4), stroke (ORR 2.0-2.8), heart disease (ORR 1.6-1.9), or diabetes (ORR 1.7-2.2). In addition, greater risk for physical function difficulties was associated with psychological distress (ORR 2.2-3.0) and low PEF scores (Ͻ80% of predicted, ORR 1.7-2.1). Among retirees with COPD, 59.3% had low PEF scores compared to 23.7% without; 34.8% had psychological distress compared to 19.6% without. CONCLUSIONS: The secondary database of longitudinal data from the HRS offers valuable information for understanding factors associated with functional limitations. Mental health and lung functioning are potential areas for focusing improvement efforts. 
PRS25 FACTORS INFLUENCING SATISFACTION WITH COPD MAINTENANCE MEDICATION: CONCEPTS ELICITED THROUGH QUALITATIVE INTERVIEWS WITH PATIENTS
BACKGROUND:
Patients with COPD have demonstrated poor adherence and persistence with inhaled maintenance medications, suggesting low satisfaction with existing therapies. An understanding of the factors driving treatment satisfaction from the patient perspective is necessary to develop or modify therapies to address patients' concerns. OBJECTIVES: To examine factors influencing patients' satisfaction with COPD maintenance medications. METHODS: Fifty-two one-on-one semi-structured telephone interviews were conducted with COPD patients to gather information about attributes that influence satisfaction with COPD maintenance medication and delivery devices. Participants were selected from two sources: patients who recently exited one of two trials with aclidinium bromide via the Genuair™ inhaler(nϭ32) or non-trial patients recruited from clinics who recently received treatment with tiotropium bromide via the HandiHaler™(nϭ20). A coding scheme for categorizing responses was developed and interview transcripts were analyzed using qualitative software. RESULTS: Focus group participants had a mean age of 66.5 years; were 51.9% female; and had a diagnosis of moderate (GOLD II) to severe (GOLD III) COPD. Four components of patients' satisfaction were identified: ease of use/convenience, efficacy, onset of action, and side effects. Regarding ease of use/convenience, patients most frequently cited the importance of device portability (31%), device simplicity (27%), and whether the device indicated that a dose had been received (25%). For efficacy, patients most frequently mentioned whether the product made them feel that their airways were open and they could catch their breath (42%), that the medication kept symptoms from worsening (33%), and that the medication improved ambulatory ability (29%). Nearly half of patients (46%) noted onset of action as important. Finally, thirty-five percent of patients noted that side effects affected their satisfaction with treatment. CONCLUSIONS: Ease of use/convenience, efficacy, onset of action, and side effects drive patients' satisfaction with inhaled COPD maintenance medications. COPD medications and delivery devices that address these factors may improve patient adherence and persistence. 
PRS26 RELIABILITY AND VALIDITY OF THE EXACT-RESPIRATORY SYMPTOMS (E-RS) SCORE TO QUANTIFY THE SEVERITY OF RESPIRATORY SYMPTOMS OF COPD
OBJECTIVES:
Although respiratory symptoms are a defining feature of COPD, a standardized method for assessing their day-to-day severity suitable for testing treatment effects in clinical trials has not been established. This study examined the reliability and validity of the E-RS (EXACT-Respiratory Symptoms), a respiratory symptom score derived from the 11 respiratory items of the 14-item EXACT, a daily diary assessing exacerbations of COPD. METHODS: Content validity was assessed through analyses of qualitative data from 84 patients with COPD, including secondary analyses of data collected during EXACT development (nϭ63) and data from four new focus groups with patients without recent history of exacerbation (nϭ21). Quantitative properties were tested through secondary analyses of data from 188 stable COPD patients gathered over 7 days during the first EXACT validation study. RESULTS: Qualitative: Sample mean (SD) ageϭ65(10), 44% male, mean FEV 1 ϭ1.2(0.4) L. Patient descriptions of respiratory symptoms during stable disease were consistent with the E-RS content, wording, and structure. Quantitative: Sample mean (SD) ageϭ66 (10), 50% male, mean FEV 1 ϭ1.2(0.5) L. Factor analysis showed three subscales: RS-Breathlessness (5 items), RS-Cough & Sputum (3 items) and RS-Chest (3 items). For RS-Total and subscale scores, respectively: Reliability, internal consistency (alpha) ϭ0.88 0.86, 0.73, 0.80; test-retest (ICC) Day 1 to 7 (nϭ171) ϭ0.73; 0.71; 0.69; 0.62. Validity: Correlations (Spearman's) with St. George Respiratory Questionnaire -COPD (SGRQ-C) ϭ0.75; 0.69, 0.58, 0.52, modified Medical Research Council dyspnea scale (mMRC) ϭ0.33; 0.38, 0.24, 0.16, and rescue medication use ϭ0.32; 0.34, 0.26, 0.17 (pՅ0.05 to 0.0001). CONCLUSIONS: Results suggest the E-RS is a valid and reliable method for evaluating severity of respiratory symptoms in COPD; the daily diary structure permits assessment of day-to-day variability and severity over time. Further research is needed to evaluate performance over longer assessment periods and in response to treatment, and to refine score interpretation. 
PRS27 THE DEVELOPMENT OF A PATIENT-REPORTED OUTCOME INSTRUMENT TO EVALUATE NIGHTTIME SYMPTOMS OF COPD
OBJECTIVES:
There is currently no validated tool to evaluate nighttime symptoms in patients with COPD. The purpose of this study was to develop and test a patient reported outcome (PRO) self-administered questionnaire for evaluating COPD symptoms experienced during the night. METHODS: A review of the literature and interviews with six clinical experts informed the development of a framework for exploring patients' experience with nighttime symptoms of COPD. Four focus groups were conducted with twenty-seven subjects who experienced COPD symptoms at night or in the early morning. Trained interviewers used a semi-structured interview guide, starting with open ended questions. Grounded theory was applied using qualitative analysis software to identify key concepts and determine concept saturation. A conceptual framework was developed to depict patients' experience with COPD symptoms at night. Items and response options were generated based on the qualitative data. Subsequently, one-on-one cognitive debriefing interviews were conducted with 10 COPD patients to assess item readability, comprehensive-A141 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) A 1 -A 2 1 4 
